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Although efficacy still merely needs to be defined with regard to the surrogate end-point, ie, blood pressure (and not with regard to morbidity and mortality), all antihypertensive drugs must be able to lower blood pressure and to do so over the full dosing interval which is, in most instances, 24 hours. Thus, we can be reassured that several statistically highly significant studies have documented that losartan's antihypertensive efficacy was greater than placebo and that this also was true at the end of the dosing interval. How then, is it possible that in the study of Mallion et al 2 the antihypertensive efficacy of losartan during the last 6 h of a 24-h cycle was not different from placebo and that it was significantly inferior to telmisartan?
Several points need to be discussed before we can draw any conclusions: (1) The effects of losartan were, indeed, numerically different from placebo, although this difference did not reach statistical significance. Indeed, a reduction of 6 mm Hg in diastolic pressure was observed with losartan in clinic measurements, but this was merely 2.5 mm Hg better than placebo. With a greater number of patients, the difference might have become statistically significant although still not necessarily clinically relevant. Also, the FDA requires that clinic blood pressure levels and not 24-h ambulatory blood pressure monitoring are used to establish efficacy. Conceivably, losartan which has a relatively short half-life, may provide a less comprehensive coverage of a 24-h period than other longer acting angiotensin receptor inhibitors, such as telmisartan. 3 (2) Several other comparative studies also documented that irbesartan, 4 dose of 50 mg, the recommendation of the manufacturer is not to uptitrate but rather to add a low dose diuretic. 8 When looking back on the history of hypertension, it is distinctly unusual to market an antihypertensive drug in just one strength. However, there are substantial data that up-titration from 50 to 100 or even 150 mg with losartan does little if anything to increase antihypertensive efficacy. 9 What then are the reasons for losartan's shallow dose response curve and its relative loss of efficacy at the end of the dosing interval?
Losartan exerts most of its antihypertensive effect through its metabolite EXP 3174 and needs to be converted by the liver to this active metabolite. Unfortunately, losartan and its active metabolite EXP 3174 compete for the same AII-1 receptors. The efficacy of losartan alone on blood pressure is considerably less marked than that of EXP 3174. Thus, by occupying the receptor, the weak antagonist losartan may prevent the more powerful EXP 3174 from exerting its full antihypertensive effect. In contrast, with most other angiotensin receptor antagonists the active compound binds directly with the AII-1 receptor and can exert its full antihypertensive power. It is not surprising, therefore, that some of these compounds are more powerful and have a more prolonged duration of action than losartan.
Clearly, the differences between, ie, telmisartan and losartan as documented in the thorough study of Mallion et al 2 are relatively small, and the clinical significance of such a difference in the blood pressure lowering potency remains to be determined. Possibly a twice-a-day dosing of losartan could improve blood pressure control during the last 6 h of a 24-h period. However, good blood pressure control during these last 6 h is particularly important because of the excessive risk of cardiovascular events that have been documented during this time period, ie, the early morning hours. All other factors being equal, a compound that has more powerful and longer lasting antihypertensive efficacy when given once a day, such as telmisartan, should be preferred over one that seems to lose part of its antihypertensive efficacy at the end of the dosing interval, such as losartan.
